While the pro-immunogenic conditions present after doxorubicin treatment are favorable for the clearance of leukemic cells, microenvironmental IL-6 production—which is increased by the presence of leukemic cells—suppresses the expected anti-cancer immune responses. The gene discussed is IL6; the disease is cancer.